Get informed when a big investor buys or sells
+ FollowOvervalued by 116.4% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $107.64 Million |
|---|---|
| Enterprise Value | $125.01 Million |
| Earnings per Share | $-0.06 |
| Beta | 2.52 |
| Outstanding Shares | 74,233,667 |
| P/E Ratio | -20.35 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | -1.45 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -47.58 |
| Enterprise Value to Net Income | -27 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -0.74 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.60%▼ 0.07% |
|---|---|
| Total Invested | $903,892▼ 10.56% |
| Investors Holding | 17▼ 2.00% |
Jyong Biotech Ltd. is a Taiwanese biotechnology enterprise dedicated to the research, development, and market introduction of botanical therapeutics, specifically aimed at addressing diseases of the urinary system. Its operations are orc...